Select Page

Ljubljana, Slovenia, Oct. 06, 2020 (GLOBE NEWSWIRE) — Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares.